Covered recipient · General Payments record
RAMI Y HADDAD
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$8,283.12
201 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,828.09 | 188 |
| Consulting Fee | $2,487.00 | 2 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,980.00 | 1 |
| Education | $621.97 | 6 |
| Long term medical supply or device loan | $366.06 | 4 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RAMI Y HADDAD
NPI 1710072624 · CMS profile ID 77195
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
OAK LAWN, IL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1710072624?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RAMI Y HADDAD, NPI 1710072624, CMS profile ID 77195. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710072624?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). RAMI Y HADDAD, NPI 1710072624, CMS profile ID 77195. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710072624?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- RAMI Y HADDAD, NPI 1710072624, CMS profile ID 77195, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 5; records 101–150 of 201 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1710072624?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
201 matching records · $8,283.12 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 201.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | $12.71 | 07/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930849849 | CMS |
| Seagen Inc. | $25.01 | 06/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 904083881 | CMS |
| ARRAY BIOPHARMA INC | $12.10 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949153723 | CMS |
| ARRAY BIOPHARMA INC | $2.59 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949176695 | CMS |
| GlaxoSmithKline, LLC. | $21.30 | 06/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944747593 | CMS |
| Amgen Inc. | $27.05 | 06/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939846167 | CMS |
| Amgen Inc. | $15.10 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939214037 | CMS |
| EMD Serono, Inc. | $18.56 | 06/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941526991 | CMS |
| Novartis Pharmaceuticals Corporation | $99.70 | 06/15/2022 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893721575 | CMS |
| Lilly USA, LLC | $6.08 | 06/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918231913 | CMS |
| E.R. Squibb & Sons, L.L.C. | $12.57 | 06/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932659141 | CMS |
| Genentech USA, Inc. | $25.66 | 06/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950769871 | CMS |
| Janssen Pharmaceuticals, Inc | $13.84 | 06/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886178855 | CMS |
| Novartis Pharmaceuticals Corporation | $16.18 | 06/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893721551 | CMS |
| Global Blood Therapeutics, Inc. | $14.67 | 06/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 942705901 | CMS |
| Janssen Biotech, Inc. | $32.12 | 06/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885875429 | CMS |
| PFIZER INC. | $7.53 | 06/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949176699 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.42 | 06/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915658137 | CMS |
| PFIZER INC. | $12.21 | 06/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949176697 | CMS |
| Novartis Pharmaceuticals Corporation | $19.68 | 06/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893721549 | CMS |
| Exelixis Inc. | $1,980.00 | 06/02/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932463533 | CMS |
| Incyte Corporation | $13.25 | 06/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 943009265 | CMS |
| AstraZeneca Pharmaceuticals LP | $99.95 | 06/01/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914754551 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $21.96 | 06/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890340867 | CMS |
| Amgen Inc. | $42.41 | 05/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939214035 | CMS |
| Novartis Pharmaceuticals Corporation | $12.82 | 05/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893721547 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.73 | 05/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932658997 | CMS |
| Amgen Inc. | $5.55 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939846165 | CMS |
| Celgene Corporation | $14.96 | 05/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932659137 | CMS |
| Merck Sharp & Dohme LLC | $28.00 | 05/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944350523 | CMS |
| Astellas Pharma US Inc | $7.83 | 05/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940188761 | CMS |
| Novartis Pharmaceuticals Corporation | $99.70 | 05/16/2022 | Long term medical supply or device loan | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893721571 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.47 | 05/12/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 915464897 | CMS |
| Merck Sharp & Dohme LLC | $21.29 | 05/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944163649 | CMS |
| Regeneron Healthcare Solutions, Inc. | $7.72 | 05/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927190299 | CMS |
| PFIZER INC. | $15.10 | 05/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949132017 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.64 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932659135 | CMS |
| PFIZER INC. | $13.02 | 05/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949131321 | CMS |
| Genentech USA, Inc. | $12.81 | 04/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950772727 | CMS |
| Exelixis Inc. | $27.65 | 04/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932462033 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.40 | 04/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932658989 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1.46 | 04/28/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932658991 | CMS |
| Pharmacyclics LLC, an AbbVie Company | $18.21 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890340865 | CMS |
| Regeneron Healthcare Solutions, Inc. | $12.90 | 04/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 927190295 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $9.47 | 04/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955648571 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3.49 | 04/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955648573 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.40 | 04/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 932658981 | CMS |
| Janssen Biotech, Inc. | $18.89 | 04/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 885875381 | CMS |
| Novartis Pharmaceuticals Corporation | $16.96 | 04/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 893721543 | CMS |
| Genentech USA, Inc. | $20.22 | 04/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950781785 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $296,277.60 | 45 |
| PY2024 | Principal investigator | $240,615.11 | 35 |
| PY2023 | Principal investigator | $454,295.09 | 196 |
| PY2022 | Principal investigator | $143,765.80 | 37 |
| PY2021 | Recipient | $2,614.20 | 1 |
| PY2021 | Principal investigator | $182,879.65 | 54 |
| PY2020 | Principal investigator | $77,734.59 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
45 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 12/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233737007 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,408.63 | 12/31/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS, LLC | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190309130 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 11/30/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233737005 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 10/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233737003 |
| Principal investigator 1 | PFIZER INC. | $956.00 | 10/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228714196 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 09/30/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736983 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 09/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941970 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 09/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942004 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 09/02/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228748587 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 08/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736985 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 07/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736987 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941959 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 07/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942021 |
| Principal investigator 1 | PFIZER INC. | $956.00 | 07/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228745734 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $11,400.00 | 07/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185542464 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 06/30/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736989 |
| Principal investigator 1 | PFIZER INC. | $1,125.00 | 06/30/2025 | Non-covered Recipient Entity US ONCOLOGY RESEARCH LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228784289 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 06/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941913 |
| Principal investigator 1 | AstraZeneca UK Limited | $4,000.00 | 06/06/2025 | Non-covered Recipient Entity THE US ONCOLOGY NETWORK | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185542462 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 05/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736991 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $55,547.00 | 05/12/2025 | Non-covered Recipient Entity Affiliated Oncologists, Llc | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235999201 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $23,625.00 | 05/02/2025 | Non-covered Recipient Entity Us Oncology Res Llc | A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530400 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,750.00 | 04/30/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185542458 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 04/30/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736993 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941926 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 04/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941947 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $150.00 | 04/15/2025 | Non-covered Recipient Entity Affiliated Oncologists | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174942032 |
| Principal investigator 1 | PFIZER INC. | $956.00 | 04/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228747580 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 03/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736995 |
| Principal investigator 1 | Mirati Therapeutics, Inc. | $120,670.85 | 03/28/2025 | Non-covered Recipient Entity Us Oncology Res Llc | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | No dispute reported | 06/30/2026 | 1236530394 |
| Principal investigator 1 | Amgen Inc. | $133.36 | 03/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS, LLC | Molecularly-Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium | No dispute reported | 06/30/2026 | 1246638911 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Affiliated Oncologists Llc Ste 109 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941936 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 03/15/2025 | Non-covered Recipient Entity Affiliated Oncologists Llc Ste 109 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941993 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $975.00 | 02/28/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736997 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1,000.00 | 02/28/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233736999 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $31,000.00 | 02/21/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) | No dispute reported | 06/30/2026 | 1185542460 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5,000.00 | 01/31/2025 | Non-covered Recipient Entity Affiliated Oncologists | A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206) | No dispute reported | 06/30/2026 | 1233737001 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $3,664.43 | 01/27/2025 | Non-covered Recipient Entity Affiliated Oncologists, Llc | A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy as First-line Treatment for Participants with Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 Expression 1% | No dispute reported | 06/30/2026 | 1235999203 |
| Principal investigator 1 | Amgen Inc. | $2,550.00 | 01/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS, LLC | An Open-label, Phase 2 Study Treating Subjects With First or Second Relapse of Multiple Myeloma With Carfilzomib, Pomalidomide, and Dexamethasone (KPd) | No dispute reported | 06/30/2026 | 1246638907 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $510.00 | 01/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS, LLC | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185542456 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $380.00 | 01/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS, LLC | A Retrospective Analysis of Biomarker Testing Variance and Treatment Patterns among Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) in the US Oncology Network Community | No dispute reported | 06/30/2026 | 1185542466 |
| Principal investigator 1 | Eli Lilly and Company | $316.63 | 01/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS - SOUTHLAND ONCOLOGY | Not supplied | No dispute reported | 06/30/2026 | 1187873223 |
| Principal investigator 1 | Eli Lilly and Company | $956.00 | 01/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS - SOUTHLAND ONCOLOGY | EMONARCHER: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF ABEMACICLIB PLUS STANDARD ADJUVANT ENDOCRINE THERAPY IN PARTICIPANTS WITH HIGH-RISK, NODE-POSITIVE, HR+, HER2+ EARLY BREAST CANCER WHO HAVE COMPLETED ADJUVANT HER2-TARGETED THERAPY | No dispute reported | 06/30/2026 | 1187880191 |
| Principal investigator 1 | Janssen Scientific Affairs, LLC | $16.67 | 01/15/2025 | Non-covered Recipient Entity Affiliated Oncologists Llc Ste 109 | MYLUNG Consortium Part 3: Observational Study (MYLUNG) | No dispute reported | 06/30/2026 | 1174941981 |
| Principal investigator 1 | PFIZER INC. | $956.00 | 01/15/2025 | Non-covered Recipient Entity AFFILIATED ONCOLOGISTS LLC | A PHASE 2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH METASTATIC SOLID MALIGNANCIES | No dispute reported | 06/30/2026 | 1228746721 |